参考文献/References:
[1] 中华医学会内分泌学分会.原发性醛固酮增多症诊断治疗的专家共识(2020版)[J].中华内分泌代谢杂志,2020,36(9):727-736.DOI:10.3760/cma.j.cn311282-20200615-00444.
[2] Williams TA,Lenders JWM,Mulatero P,et al.Outcomes after adrenalectomy for unilateral primary aldosteronism:an international consensus on outcome measures and analysis of remission rates in an international cohort [J].Lancet Diabetes Endocrinol,2017,5(9):689-699.DOI:10.1016/s2213-8587(17)30135-3.
[3] Williams TA,Gomez-Sanchez CE,Rainey WE,et al.International histopathology consensus for unilateral primary aldosteronism[J].J Clin Endocrinol Metab,2021,106(1):42-54.DOI:10.1210/clinem/dgaa484.
[4] Curnow KM,Tusie-Luna MT,Pascoe L,et al.The product of the CYP11B2 gene is required for aldosterone biosynthesis in the human adrenal cortex[J].Mol Endocrinol,1991,5(10):1513-1522.DOI:10.1210/mend-5-10-1513.
[5] Nishimoto K,Nakagawa K,Li D,et al.Adrenocortical zonation in humans under normal and pathological conditions[J].J Clin Endocrinol Metab,2010,95(5):2296-2305.DOI:10.1210/jc.2009-2010.
[6] Nishimoto K,Seki T,Hayashi Y,et al.Human adrenocortical remodeling leading to aldosterone-producing cell cluster generation[J].Int J Endocrinol,2016,2016:7834356.DOI:10.1155/2016/7834356.
[7] Lifton RP,Dluhy RG,Powers M,et al.A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension[J].Nature,1992,355(6357):262-265.DOI:10.1038/355262a0.
[8] Gomez-Sanchez CE,Qi X,Velarde-Miranda C,et al.Development of monoclonal antibodies against human CYP11B1 and CYP11B2[J].Mol Cell Endocrinol,2014,383(1-2):111-117.DOI:10.1016/j.mce.2013.11.022
[9] De Sousa K,Boulkroun S,Baron S,et al.Genetic,Cellular,and Molecular Heterogeneity in Adrenals With Aldosterone-Producing Adenoma[J].Hypertension,2020,75(4):1034-1044.DOI:10.1161/HYPERTENSIONAHA.119.14177.
[10] Wang H,Wang F,Zhang Y,et al.Surgical outcomes of aldosterone-producing adenoma on the basis of the histopathological findings[J].Front Endocrinol,2021,12:663096.DOI:10.3389/fendo.2021.663096.
[11] Nanba K,Omata K,Gomez-Sanchez CE,et al.Genetic characteristics of aldosterone-producing adenomas in Blacks[J].Hypertension,2019,73(4):885-892.DOI:10.1161/HYPERTENSIONAHA.118.12070.
[12] 王慧萍,崔云英,马晓森,等.特发性醛固酮增多症的病理分型和手术预后[J].基础医学与临床,2021,41(10):1481-1485.DOI:10.3969/j.issn.1001-6325.2021.10.015.
[13] Omata K,Satoh F,Morimoto R,et al.Cellular and Genetic Causes of Idiopathic Hyperaldosteronism[J].Hypertension,2018,72(4):874-880.DOI:10.1161/HYPERTENSIONAHA.118.11086.
[14] Nishimoto K,Koga M,Seki T,et al.Immunohistochemistry of aldosterone synthase leads the way to the pathogenesis of primary aldosteronism[J].Mol Cell Endocrinol,2017,441:124-133.DOI:10.1016/j.mce.2016.10.014.
[15] Mete O,Erickson LA,Juhlin CC,et al.Overview of the 2022 WHO classification of adrenal cortical tumors[J].Endocr Pathol,2022,33(1):155-196.DOI:10.1007/s12022-022-09710-8.
[16] Meyer LS,Handgriff L,Lim JS,et al.Single-Center prospective cohort study on the histopathology,genotype,and postsurgical outcomes of patients with primary aldosteronism[J].Hypertension,2021,78(3):738-746.DOI:10.1161/HYPERTENSIONAHA.121.17348.
[17] Budwit-Novotny DA,Mccarty KS,Cox EB,et al.Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody[J].Cancer Res,1986,46(10):5419-5425.
[18] Sun L,Jiang Y,Xie J,et al.Immunohistochemical analysis of CYP11B2,CYP11B1 and β-catenin helps subtyping and relates with clinical characteristics of unilateral primary aldosteronism[J].Front Mol Biosci,2021,8:751770.DOI:10.3389/fmolb.2021.751770.
[19] Lin JH,Peng KY,Kuo YP,et al.Aldosterone-producing nodules and CYP11B1 signaling correlate in primary aldosteronism[J].Endocrine-related cancer,2022,29(2):59-69.DOI:10.1530/erc-21-0287.
[20] Ono Y,Nakamura Y,Maekawa T,et al.Different expression of 11β-hydroxylase and aldosterone synthase between aldosterone-producing microadenomas and macroadenomas[J].Hypertension,2014,64(2):438-444.DOI:10.1161/HYPERTENSIONAHA.113.02944.
[21] Ahn CH,Na HY,Park SY,et al.Expression of CYP11B1 and CYP11B2 in adrenal adenoma correlates with clinical characteristics of primary aldosteronism[J].Clin Endocrinol(Oxf),2022,96(1):30-39.DOI:10.1111/cen.14628.
[22] Shariq OA,Mehta K,Thompson GB,et al.Primary aldosteronism:Does underlying pathology impact clinical presentation and outcomes following unilateral adrenalectomy?[J].World J Surg,2019,43(10):2469-2476.DOI:10.1007/s00268-019-05059-y.
[23] Volpe C,Hamberger B,Zedenius J,et al.Impact of immunohistochemistry on the diagnosis and management of primary aldosteronism:an important tool for improved patient follow-up[J].Scand J Surg,2020,109(2):133-142.DOI:10.1177/1457496918822622.
[24] Xie J,Zhang C,Wang X,et al.Exploration of KCNJ5 somatic mutation and CYP11B1/CYP11B2 staining in multiple nodules in primary aldosteronism[J].Front Med(Lausanne),2022,9:823065.DOI:10.3389/fmed.2022.823065.
[25] Nanba K,Yamazaki Y,Bick N,et al.Prevalence of somatic mutations in aldosterone-producing adenomas in Japanese patients[J].J Clin Endocrinol Metab,2020,105(11):e4066-4073.DOI:10.1210/clinem/dgaa595.
[26] 陈亮,宋颖,肖明,等.不同基因突变的醛固酮瘤患者的临床生化及免疫组化特征[J].中华内分泌代谢杂志,2021,37(1):45-51.DOI:10.3760/cma.j.cn311282- 20200522-00373.
[27] Omata K,Anand SK,Hovelson DH,et al.Aldosterone-producing cell clusters frequently harbor somatic mutations and accumulate with age in normal adrenals[J].J Endocr Soc,2017,1(7):787-799.DOI:10.1210/js.2017-00134.
[28] Yang Y,Gomez-Sanchez CE,Jaquin D,et al.Primary aldosteronism:KCNJ5 mutations and adrenocortical cell growth[J].Hypertension,2019,74(4):809-816.DOI:10.1161/HYPERTENSIONAHA.119.13476.
相似文献/References:
[1]高海静,温俊平.肾上腺醛固酮腺瘤术后临床转归的影响因素[J].国际内分泌代谢杂志,2016,36(01):58.[doi:10.3760/cma.j.issn.1673-4157.2016.01.015]
Gao Haijing,Wen Junping..Influence factors of postoperative clinical outcomes for patients with adrenal aldosteronoma[J].International Journal of Endocrinology and Metabolism,2016,36(05):58.[doi:10.3760/cma.j.issn.1673-4157.2016.01.015]
[2]钟珊,宋筱筱,徐小红.原发性醛固酮增多症分型诊断研究进展[J].国际内分泌代谢杂志,2020,40(05):327.[doi:10.3760/cma.j.cn121383-20200203-02006]
Zhong Shan,Song Xiaoxiao,Xu Xiaohong.Research progress of subtype diagnosis in primary hyperaldosteronism[J].International Journal of Endocrinology and Metabolism,2020,40(05):327.[doi:10.3760/cma.j.cn121383-20200203-02006]
[3]郑爱琳,宋颖,罗蓉,等.关于原发性醛固酮增多症诊治的常见误区[J].国际内分泌代谢杂志,2021,41(02):73.[doi:10.3760/cma.j.cn121383-20210119-01054]
Zheng Ailin,Song Ying,Luo Rong,et al.Misunderstandings in the diagnosis and treatment of primary aldosteronism[J].International Journal of Endocrinology and Metabolism,2021,41(05):73.[doi:10.3760/cma.j.cn121383-20210119-01054]
[4]王慧萍,童安莉.原发性醛固酮增多症相关的基因突变研究进展[J].国际内分泌代谢杂志,2021,41(02):87.[doi:10.3760/cma.j.cn121383-20200706-07013]
Wang Huiping,Tong Anli..Research progress on gene mutation related primary aldosteronism[J].International Journal of Endocrinology and Metabolism,2021,41(05):87.[doi:10.3760/cma.j.cn121383-20200706-07013]
[5]郭富饶,李启富,徐智新.血浆肾素测定方法的新进展及临床意义[J].国际内分泌代谢杂志,2021,41(06):628.[doi:10.3760/cma.j.cn121383-20210315-03038]
Guo Furao,Li Qifu,Xu Zhixin..Advances and clinical value of plasma renin measurement[J].International Journal of Endocrinology and Metabolism,2021,41(05):628.[doi:10.3760/cma.j.cn121383-20210315-03038]
[6]许媛 许岚 张丽华 李启富 杨淑敏.中国原发性醛固酮增多症诊断现状调查研究[J].国际内分泌代谢杂志,2022,42(04):288.[doi:10.3760/cma.j.cn121383-20201221-12058]
Xu Yuan,Xu Lan,Zhang Lihua,et al.Investigation on current status of diagnosis of primary aldosteronism in China[J].International Journal of Endocrinology and Metabolism,2022,42(05):288.[doi:10.3760/cma.j.cn121383-20201221-12058]
[7]谢梦晨,郭洋洋,黄金慧,等.原发性醛固酮增多症基因型与临床表型关系的研究进展[J].国际内分泌代谢杂志,2023,43(03):216.[doi:10.3760/cma.j.cn121383-20220307-03015]
Xie Mengchen,Guo Yangyang,Huang Jinhui,et al.Association of genotype and clinical phenotype of primary aldosteronism[J].International Journal of Endocrinology and Metabolism,2023,43(05):216.[doi:10.3760/cma.j.cn121383-20220307-03015]